The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company’s OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the company, the European patent will protect OX640 until May 2041.
OX640 intranasal adrenaline is based on the same technology as the company’s OX125 intranasal nalmefene and OX124 intranasal naloxone for the treatment of opioid overdose, Orexo’s amorphOX particle engineering platform.
Orexo President and CEO Nikolaj Sørensen commented, “OX640 is a unique and innovative new product to be used for the emergency treatment of allergic reactions. I am pleased that the innovation has been recognized by the EPO, an important step towards making this life-saving medication available for patients in Europe. In addition to its excellent chemical stability, the clinical data that are anticipated later this year, and its significant market potential, securing strong patent protection for OX640 is clearly important for our discussions with potential partners.”
Read the Orexo press release.
